Circulation of Pneumocystis dihydropteroate synthase mutants in France

Solène Le Gal1, Céline Damiani, Maëla Perrot

  • 1UEB, University of Brest, LUBEM EA 3882, SFR 148, Brest, France. solene.legal@chu-brest.fr

Insights

Prevalence of Pneumocystis jirovecii dihydropteroate synthase mutants in western France is very low. Mutant strains likely circulate from Paris via infected travelers, not posing a public health risk.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Public Health

Background:

  • Limited data exists on Pneumocystis jirovecii dihydropteroate synthase (DHPS) mutant prevalence in France.
  • Understanding geographic distribution of P. jirovecii DHPS mutants is crucial for treatment and prevention strategies.

Purpose of the Study:

  • To determine the prevalence of P. jirovecii DHPS mutants in the Brest region of western France.
  • To investigate the origin and transmission patterns of P. jirovecii DHPS mutants in the study population.

Main Methods:

  • Retrospective analysis of archival pulmonary specimens from 85 P. jirovecii-infected patients.
  • DHPS genotyping using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
  • Medical chart review to determine patient residence and travel history.

Main Results:

  • Mutant P. jirovecii DHPS strains were identified in 3% (2/66) of patients with successful typing.
  • Both patients with mutants resided in Paris, suggesting transmission from a high-prevalence area.
  • The corrected prevalence of mutants among Brest residents was 0% (0/63).

Conclusions:

  • Patient's usual city of residence, not diagnosis location, predicts mutant P. jirovecii infection.
  • Infected travelers may introduce P. jirovecii DHPS mutants from high-prevalence areas like Paris to low-prevalence regions.
  • P. jirovecii infections involving DHPS mutants do not currently represent a significant public health concern in western France.